（原标题：麦济生物冲刺港股IPO） 根据弗若斯特沙利文的数据，过敏性及自身免疫疾病药物的市场规模庞大。2023年全球过敏性疾病药物 市场规模为618亿美元，预计到2032年将扩大至1222亿美元，2023年至2032年的复合年增长率为7.9%。 2023年中国过敏性疾病药物市场规模为72亿美元，并预期将持续其强劲增长，到2032年将达310亿美 元，2023年至2032年的复合年增长率预计为17.5%。 自身免疫疾病药物的全球市场规模在2023年为1338亿美元，预期2032年将达到1923亿美元，2023年至 2032年的复合年增长率为4.1%。由于中国自身免疫疾病的诊断率较低，市场规模一直较小，但随着人 们对创新疗法的意识提高及潜在的营销活动，预期市场规模在未来将出现大幅增长。整体市场预期将由 2023年的38亿美元增加至2032年的266亿美元，2023年至2032年的复合年增长率为24.0%。 截至最后实际可行日期，麦济生物持有20项授权专利，包括8项中国内地授权专利及12项其他司法管辖 区授权专利；以及23项专利申请，包括18项其他司法管辖区专利申请及5项PCT专利申请。但是该公司 目前没有任何已获 ...

Company Overview - Hunan Maijizhi Biotechnology Co., Ltd. (Maijizhi) has submitted a listing application to the Hong Kong Stock Exchange, with CICC as the sole sponsor [1] - The company is a clinical-stage biopharmaceutical firm focused on discovering, developing, and commercializing innovative biologics to address unmet medical needs in allergic and autoimmune diseases [3] Product Pipeline - Since its establishment in 2016, Maijizhi has developed a robust pipeline of eight innovative candidate products, including core product MG-K10, key products MG-014 and MG-013, all of which are next-generation long-acting antibodies discovered and developed through the company's proprietary technology platform [3] - MG-K10 is a potential best-in-class, self-developed long-acting anti-IL-4Rα antibody currently undergoing clinical trials for eight indications, including atopic dermatitis and asthma, showing promising safety and efficacy data [3] Market Potential - The global market for allergic disease drugs is projected to grow from $61.8 billion in 2023 to $122.2 billion by 2032, with a compound annual growth rate (CAGR) of 7.9% [4] - The Chinese market for allergic disease drugs is expected to grow from $7.2 billion in 2023 to $31 billion by 2032, with a CAGR of 17.5% [4] - The global market for autoimmune disease drugs is anticipated to increase from $133.8 billion in 2023 to $192.3 billion by 2032, with a CAGR of 4.1% [4] - The Chinese autoimmune disease market is expected to grow significantly, from $3.8 billion in 2023 to $26.6 billion by 2032, with a CAGR of 24% [4] Financial Performance - For the fiscal year 2023, Maijizhi reported revenues of RMB 8.722 million, with total losses of approximately RMB 252.942 million [6][7] - In 2024, the company expects revenues to increase to RMB 24,000, while losses are projected to be around RMB 178.308 million [6][7] - The company has no approved or commercialized products yet but is advancing multiple candidates towards the BLA application stage [5]